BC Extra | Mar 1, 2018
Politics & Policy

Biopharma wants another bite at the donut hole

Lobbyists for the biopharmaceutical industry are scrambling to use a must-pass spending bill as a vehicle to roll back provisions in a recently enacted law that would impose tens of billions of dollars in costs...
BC Week In Review | Dec 15, 2014
Company News

Cubist, Merck deal

Merck will acquire Cubist for $102 per share and $1.1 billion in assumption of debt in a deal valued at $9.5 billion. The cash offer of $102 per share, or $8.4 billion, represents a 37%...
BioCentury | Oct 27, 2014
Finance

Waiting for better times

Poised to complete the fourth-largest European biotech IPO since 2008, the road show for Molecular Partners AG had the poor luck of coinciding with the largest one-week drop in the broader capital markets since the...
BioCentury | Jul 28, 2014
Finance

Staying the course with half a billion

Sofinnova Ventures is sticking with what works for its second life sciences-only fund, which the firm closed last week at $500 million. The fund, the firm's ninth overall, was oversubscribed and was originally targeting $425...
BC Week In Review | Jun 16, 2014
Clinical News

Entereg alvimopan regulatory update

The majority of panelists on FDA's Anesthetic and Analgesic Drug Products Advisory Committee felt cardiovascular outcomes trials weren't warranted for peripheral mu opioid receptor ( OPRM1 ; MOR) antagonists to treat opioid-induced constipation (OIC) in patients...
BC Week In Review | Jun 16, 2014
Clinical News

Relistor methylnaltrexone regulatory update

The majority of panelists on FDA's Anesthetic and Analgesic Drug Products Advisory Committee felt cardiovascular outcomes trials weren't warranted for peripheral mu opioid receptor ( OPRM1 ; MOR) antagonists to treat opioid-induced constipation (OIC) in patients...
BC Extra | Jun 14, 2014
Company News

Nektar up on FDA panel decision for OIC

Nektar Therapeutics (NASDAQ:NKTR) jumped $1.35 (11%) to $13.89 on Friday after the majority of panelists on FDA's Anesthetic and Analgesic Drug Products Advisory Committee said on Thursday that cardiovascular outcomes trials weren't warranted for peripheral...
BC Extra | Jun 12, 2014
Top Story

FDA panel discusses CV outcomes trials in OIC

The majority of panelists on FDA's Anesthetic and Analgesic Drug Products Advisory Committee felt cardiovascular outcomes trials weren't warranted for peripheral mu opioid receptor ( OPRM1 ; MOR) antagonists to treat opioid-induced constipation (OIC) in patients...
BC Extra | Jun 10, 2014
Company News

FDA reviewers question CV risk with OIC drugs

FDA reviewers said controlled, long-term safety data "seem critical" to assess the cardiovascular risk of peripherally acting opioid receptor antagonists, though the reviewers cautioned that this is contingent on whether a CV event rate imbalance...
BioCentury | Apr 28, 2014
Finance

Venture hots up

Private biotechs have raised $3.1 billion since the start of the year, double the $1.5 billion raised in the same period last year. At least one investor contacted by BioCentury expects the pace to continue...
Items per page:
1 - 10 of 273